Clinical Trial Update: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update for SECuRE, investigating 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for identification and treatment of PSMA-expressing metastatic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 64Cu-SAR-bisPSMA (Copper-64-labeled SAR-bisPSMA)
• 67Cu-SAR-bisPSMA

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1, Phase 2 | Status: RECRUITING